AlphAIAlphAI — Financial news for AI agents
investing.comOCT 302 min read$INSM

Goldman Sachs reiterates Insmed stock rating on Brinsupri beat

Goldman Sachs maintained a Buy rating and $194 price target for Insmed (INSM) after its quarterly results beat estimates. Brinsupri revenue was $400.1M, exceeding expectations. Insmed raised its 2026 guidance for Brinsupri to $1.35B-$1.40B. The stock rose 19.5% to $111.59. Analysts have revised earnings upwards, with price targets ranging from $165 to $243.

Original reporting
investing.com
Published Oct 30, 2026, 9:10 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 9:24 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$INSM
Bullish
high confidence
Mentioned
$INSM
Relevance
9/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$INSMBullishHigh
01

Why it matters

The earnings beat and guidance lift are likely to drive short‑term buying pressure, especially in pre‑market hours, as analysts raise price targets.

02

Market read

First report of Insmed's earnings beat and guidance raise; material for traders looking for biotech upside.

03

What to watch

Potential regulatory delays for the PALM program could temper upside.

Relevance 9/10Novelty 8/10Timing: today

Background

Goldman Sachs reiterated a Buy rating on Insmed after the company posted quarterly results that beat revenue estimates and lifted its Brinsupri guidance.

Company-level read

Ticker impact

$INSMBullishHigh confidence
Context

Insmed reported Q3 revenue beat and raised FY2026 Brinsupri guidance, prompting a Goldman Sachs reiteration of Buy and $194 price target.

Expected impact

likely upward pressure as the market prices in the higher guidance and buy rating

Evidence & confidence

Revenue beat and guidance lift are fresh, material facts for a large‑cap biotech; analysts have increased targets, indicating a bullish outlook.

Market effects

Sector

Biotech sector may see broader optimism as a peer posts strong earnings and guidance.

Regional

U.S. biotech stocks could rally in pre‑market trading.

Global

Limited to investors tracking U.S. biotech earnings.

Counterpoint

What could challenge this read

The guidance raise may already be priced in; downside risk if upcoming Arikayce label expansion stalls.

Key entities

  • company
    Insmed

    Biopharma developing Brinsupri and Arikayce.

  • analyst
    Goldman Sachs

    Reiterated Buy rating and raised price target to $194.

Read at source← All news

StoryInsmed raises 2026 revenue guidance after strong third-quarter results

Also covered by

4 outlets

Related articles

OCT 30
$INSMHighAI 8/10

Why Did Insmed Stock Jump?

Insmed (INSM) shares rose 15.1% on October 29, 2026, after reporting Q3 2026 results. Revenue of $524.4M beat estimates, but loss per share was wider. BRINSUPRI revenue grew 29% QoQ, and guidance was raised. R&D and sales costs increased 40% YoY. The stock is down 32.5% over the past year.

finance.yahoo.com2 min
OCT 29
$INSMMed

Insmed Inc (INSM) Q3 2026 Earnings Call Highlights: Brinsupri Hits Blockbuster Status

Insmed Inc (INSM) reported positive Q3 2026 earnings, with Brinsupri showing strong persistency and revenue trends. The company expects cash flow positivity in 2027 and provided updates on TPIP trials and Erakase's label expansion. Dr. Martina Flammer highlighted growth opportunities in comorbid COPD and asthma bronchiectasis, with data expected in mid-2027. Insmed also discussed AI use for patient identification and the potential impact of real-world studies.

finance.yahoo.com2 min
OCT 29
$INSMMedAI 8/10

What Insmed (INSM) Said on Its Q3 Earnings Call

Insmed (INSM) reported Q3 earnings, highlighting AI diagnostic tools for bronchiectasis, expected to share findings in 2027. FDA granted priority review for ARIKAYCE's sNDA, with a target action date of Jan. 28, 2027. The company expects cash-flow positivity in 2027. Insmed also provided updates on its pipeline, including TPIP and INS1033 programs. Cost of product revenues was $78.2 million, or 14.9% of revenue, with combined R&D and SG&A expenses up 40% year over year.

finance.yahoo.com2 min
OCT 29
$INSMHighAI 8/10

Insmed (INSM) Q3 2026 Earnings Call Transcript

Insmed (INSM) reported Q3 2026 revenue of $400.1M for BRINSUPRI, up 29% sequentially. The company raised its 2026 revenue guidance to $1.35B-$1.4B. Insmed expects its lead respiratory assets to exceed $14B in peak sales, with BRINSUPRI potentially reaching $7B+ and TPIP $6B+.

finance.yahoo.com3 min
OCT 29
HighAI 8/10

Insmed surges on Q3 revenue beats, revenue guidance range raise

Insmed's stock rose 13% after Q3 results beat revenue estimates. The company raised full-year revenue guidance for Brinsupri and Arikayce. Q3 GAAP EPS was -$0.46, an improvement from -$1.75 last year. Brinsupri revenue grew 29% QoQ, while Arikayce revenue increased 9%. Cash reserves were ~$1.15B at Q3's end.

tradingview.com1 min